To include your compound in the COVID-19 Resource Center, submit it here.

Lotronex alosetron selective 5-HT3 receptor antagonist regulatory update

At the request of the FDA, GLXO withdrew Lotronex from the U.S. market

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE